Market Place
Sourcing Support
Bright Minds to Present Data at American Epilepsy Annual Meeting
21 Nov 2024 //
GLOBENEWSWIRE
Bright Minds Biosciences Closes US$35M Private Placement
04 Nov 2024 //
GLOBENEWSWIRE
Bright Minds Bio And Firefly Neuro Collaborate On BMB-101 Analysis
21 Oct 2024 //
GLOBENEWSWIRE
Bright Minds Biosciences Announces US$35 Million Placement
18 Oct 2024 //
GLOBENEWSWIRE
Firefly Collaborates With Bright Minds On Ph 1 Data BNA™
16 Oct 2024 //
GLOBENEWSWIRE
Bright Minds BMB-201 Shows Efficacy Similar To Morphine In Pain
16 Oct 2024 //
GLOBENEWSWIRE
Bright Minds Bio To Join Upcoming Science And Partner Events
03 Oct 2024 //
GLOBENEWSWIRE
Bright Minds Biosciences To Host Investor & Analyst Event
19 Sep 2024 //
GLOBENEWSWIRE
Bright Minds Initiates Phase 2 Trial Of BMB-101 In Epilepsy
12 Sep 2024 //
PR NEWSWIRE
Bright Minds Biosciences Announces Positive qEEG Data from Phase 1 Study BMB-101
08 Aug 2023 //
PRESS RELEASE
Bright Minds Announces Positive Topline Data for Phase 1 Study of BMB-101
20 Jul 2023 //
GLOBENEWSWIRE
Bright Minds Announces Effective Date of Share Consolidation
11 Jul 2023 //
GLOBENEWSWIRE
Bright Minds Announces Proposed Share Consolidation
22 Jun 2023 //
GLOBENEWSWIRE
Bright Minds Biosciences Receives a Favorable Written Opinion
19 Apr 2023 //
GLOBENEWSWIRE
Bright Minds to Present at 20th International Meeting of International Society
10 Apr 2023 //
GLOBENEWSWIRE
Bright Minds Biosciences Provides Clinical Program Updates for 2023
27 Feb 2023 //
GLOBENEWSWIRE
Bright Minds Biosciences Announces Non-Executive Director Appointment
17 Feb 2023 //
GLOBENEWSWIRE
Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter
08 Feb 2023 //
GLOBENEWSWIRE
Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter
27 Jan 2023 //
GLOBENEWSWIRE
Bright Minds Biosciences Announces Resignation of Board Member
09 Jan 2023 //
GLOBENEWSWIRE
Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement
02 Dec 2022 //
GLOBENEWSWIRE
Bright Minds Biosciences Announces Non-Brokered Private Placement
28 Nov 2022 //
GLOBENEWSWIRE
Bright Minds Biosciences Appoints Mark A. Smith as Chief Medical Officer
23 Nov 2022 //
GLOBENEWSWIRE
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101
31 Aug 2022 //
GLOBENEWSWIRE
Bright Minds Biosciences Announces Closing of $4 Million Unit Offering
30 Aug 2022 //
GLOBENEWSWIRE
Bright Minds Announces Pricing of Overnight Marketed Offering of Units
23 Aug 2022 //
GLOBENEWSWIRE
Bright Minds Biosciences Announces Changes to its Executive Leadership Team
27 Jun 2022 //
GLOBENEWSWIRE
Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome
12 May 2022 //
GLOBENEWSWIRE
Bright Minds Biosciences Establishes Scientific Advisory Board
02 May 2022 //
GLOBENEWSWIRE
Bright Minds Biosciences to Host Symposium on Therapeutic Developments
19 Apr 2022 //
GLOBENEWSWIRE
Bright Minds Bio Successfully Completes 28-Day Toxicology Studies
14 Mar 2022 //
GLOBENEWSWIRE
Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference
04 Jan 2022 //
GLOBENEWSWIRE
